SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6 months.

ABSTRACT:

Introduction

Serological SARS-CoV-2 assays have an important role in guiding the pandemic response. This research aimed to compare the performance of 2 antinucleocapsid assays.

Methods

Serum from 49 HCWs was analysed at baseline and 6 months using the Abbott diagnostics SARS-CoV-2 IgG assay and the Roche Diagnostics Elecsys Anti-SARS-CoV-2 total antibody assay.

Results

At baseline, 14/49 participants (29%) demonstrated antibody reactivity using the Abbott assay. At 6 months, 4/14 participants (29%) continued to demonstrate reactivity. A total of 14/49 (29%) participants had detectable antibodies at baseline using the Roche assay. In total, 13/14 (93%) of participants demonstrated antibody reactivity at 6 months. The Abbott assay showed a statistically significant diff

SUBMITTER: Kerr C 

PROVIDER: S-EPMC8262428 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature